Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PERFECT: Atezolizumab with neoadjuvant chemoradiation in resectable oesophageal cancer
2016-004744-11Phase 2Active
- Sponsor
- Academic Medical Center
- Start
- Feb 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab in esophageal cancer and gastroesophageal junction adenocarcinoma, sponsored by Academic Medical Center. Primary endpoint: Feasibility (completion of atezolizumab treatment). Started Feb 2017; status: active.
02
Drugs
atezolizumab
03
Conditions
esophageal cancergastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2016-004744-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004744-11.